Skip to main content

What the FDA labels say about taking them together

Phenytoin and suvorexant

Suvorexant's FDA label of March 10, 2025 names phenytoin in its drug interactions section; the phenytoin labels PlainMeds reads (2) do not name suvorexant. The suvorexant label: “CYP3A Inducers Suvorexant exposure can be substantially decreased when co-administered with strong CYP3A inducers.”

Check it at the source: the phenytoin FDA label on DailyMed (effective October 15, 2024, Mylan Pharmaceuticals Inc.); the suvorexant FDA label on DailyMed (effective March 10, 2025, Merck Sharp & Dohme LLC).

What does the phenytoin label say about suvorexant?

Phenytoin's label (effective October 15, 2024) and its 1 other brand-application label do not name suvorexant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Phenytek), Mylan Pharmaceuticals Inc., effective October 15, 2024 (SPL set 0f94c791-8b07-4b41-927e-c9f28bec5f60), via openFDA; the full label on DailyMed

What does the suvorexant label say about phenytoin?

Suvorexant label, drug interactions

CYP3A Inducers Suvorexant exposure can be substantially decreased when co-administered with strong CYP3A inducers (e.g., rifampin, carbamazepine and phenytoin).

Source: FDA drug label (BELSOMRA), Merck Sharp & Dohme LLC, effective March 10, 2025 (SPL set e5b72731-1acb-45b7-9c13-290ad12d3951), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

29Phenytoin generic labelers
0Suvorexant generic labelers
PhenytoinSuvorexant
Labeled forSeizures and epilepsyInsomnia
Boxed warningNoNo
Pharmacy cost (NADAC)$0.145 per capsule 100 mg capsule$15.21 per tablet 10 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?